SHINE Technologies, LLC, a next-generation fusion technology company, today announced it is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used in targeted cancer therapies. The new facility, which will operate at SHINE’s headquarters in Janesville, Wisconsin, is expected to have an initial production capacity of 100,000 doses of Lu-177 per year, with the ability to further expand production capacity to 200,000 doses per year in the future.

Lu-177 is a radioactive agent that, when paired with a cancer-seeking molecule, delivers highly targeted radiation to cancer metastases, killing cancer cells while minimizing damage to surrounding healthy cells. There are currently two Lu-177-based radiotherapies that have been commercially approved, and the market is expected to continue its rapid growth with advancements across new therapies and indications in clinical trials.

Click here to read the full article.